Evidence map›Paper›PMID 38016518›Full record

ArticleJournal of thrombosis and haemostasis : JTH2024

Evaluating the clinical validity of genes related to hemostasis and thrombosis using the Clinical Genome Resource gene curation framework.

Justyne E Ross, Shruthi Mohan, Jing Zhang, Mia J Sullivan, Loredana Bury, Kristy Lee, Isabella Futchi, Annabelle Frantz, Dara McDougal, Juliana Perez Botero and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 7 countries.

Justyne E RossDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Shruthi MohanDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jing ZhangKingMed Diagnostics, Guangzhou, Guangdong, China.
Mia J SullivanVersiti Blood Center of Wisconsin, Milwaukee, Wisconsin, USA.
Loredana BuryDepartment of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Kristy LeeDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Isabella FutchiDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Annabelle FrantzDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Dara McDougalDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Juliana Perez BoteroVersiti Blood Center of Wisconsin, Milwaukee, Wisconsin, USA; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Marco CattaneoDipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.
Nichola CooperCentre for Haematology, Imperial College London, London, UK.
Kate DownesDepartment of Haematology, University of Cambridge, Cambridge, UK.
Paolo GreseleDepartment of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Catriona KeenanHaemostasis Molecular Diagnostic Laboratory, National Coagulation Centre, St James's Hospital, Dublin, Ireland.
Alfred I LeeSection of Hematology, Yale School of Medicine, New Haven, Connecticut, USA.
Karyn MegyDepartment of Haematology, University of Cambridge, Cambridge, UK.
Pierre-Emmanuel MorangeINSERM, INRAE, C2VN, Aix Marseille University, Marseille, France; Hematology Laboratory, La Timone Hospital, APHM, Marseille, France.
Neil V MorganInstitute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Harald SchulzeInstitute of Experimental Biomedicine, Julius-Maximilians-University Wuerzburg, Wuerzburg, Germany.
Karen ZimowskiAflac Cancer and Blood Disorders Center, Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Kathleen FresonDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. Electronic address: kathleen.freson@kuleuven.be.
Michele P LambertDivision of Hematology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: LAMBERTM@chop.edu.
University of North Carolina at Chapel Hill · USUniversity of Cambridge · GBUniversity of Perugia · ITChildren's Hospital of Philadelphia · USEmory University · USImperial College London · GBInserm · FRKingmed Diagnostics · CNKU Leuven · BEMedical College of Wisconsin · USSt. James's Hospital · IEUniversity of Birmingham · GBUniversity of Milan · ITVersiti Blood Center of Wisconsin · USYale University · US

Funding

The Clinical Genome Resource – Advancing genomic medicine through biocuration and expert assessment of genes and variants at scaleU24HG009650 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JONATHAN S BERG, Jessica Ezzell Hunter · 2021 to 2026
$30.0M
The Clinical Genome Resource - Expert Curation and EHR IntegrationU41HG009650 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BERG, JONATHAN S · 2017 to 2020
$13.3M
NHGRI NIH HHS U24 HG009650NHGRI NIH HHS U41 HG009650
6 · The paper itself

Abstract

backgroundInherited bleeding, thrombotic, and platelet disorders (BTPDs) are a heterogeneous set of diseases, many of which are very rare globally. Over the past 5 decades, the genetic basis of some of these disorders has been identified, and recently, high-throughput sequencing has become the primary means of identifying disease-causing genetic variants.

objectivesKnowledge of the clinical validity of a gene-disease relationship is essential to provide an accurate diagnosis based on results of diagnostic gene panel tests and inform the construction of such panels. The Scientific and Standardization Committee for Genetics in Thrombosis and Hemostasis undertook a curation process for selecting 96 TIER1 genes for BTPDs. The purpose of the process was to evaluate the evidence supporting each gene-disease relationship and provide an expert-reviewed classification for the clinical validity of genes associated with BTPDs.

methodsThe Clinical Genome Resource (ClinGen) Hemostasis/Thrombosis Gene Curation Expert Panel assessed the strength of evidence for TIER1 genes using the semiquantitative ClinGen gene-disease clinical validity framework. ClinGen Lumping and Splitting guidelines were used to determine the appropriate disease entity or entities for each gene, and 101 gene-disease relationships were identified for curation.

resultsThe final outcome included 68 Definitive (67%), 26 Moderate (26%), and 7 Limited (7%) classifications. The summary of each curation is available on the ClinGen website.

conclusionExpert-reviewed assignment of gene-disease relationships by the ClinGen Hemostasis/Thrombosis Gene Curation Expert Panel facilitates accurate molecular diagnoses of BTPDs by clinicians and diagnostic laboratories. These curation efforts can allow genetic testing to focus on genes with a validated role in disease.

Indexed as

Blood Platelet DisordersThrombosisGenetic TestingGenetic VariationHemostasisHumansdata curationgenetic disordersgenetic variationhemostasisreliability and validitythrombosis

Identifiers

PMID38016518
PMCPMC10922649
OpenAlexW4389005557

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.